Abelacimab (anti-Factor XI), 整合素 αIIbβ3 抗体

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175444-100μg	100μg	现货
Ab175444-1mg	1mg	现货
Ab175444-5mg	5mg	现货
Ab175444-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: F11 点击查看靶蛋白信息: ITGA2B 点击查看靶蛋白信息: ITGB3

Accession#:P03951 (2) Amino Acid/Protein Metabolism (4559) coagulation factor XI Antibody (2) F11 (2) Factor XI (2) Gene ID:2160 (2)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Abelacimab (anti-Factor XI), 整合素 αIIbβ3 抗体
别名	阿贝西单抗 \| Factor XI抗体 \| Factor XI单克隆抗体 \| Factor XI药靶抗体 \| F11抗体 \| F11单克隆抗体 \| F11药靶抗体
英文别名	coagulation factor XI antibody \| Coagulation factor XIa light chain antibody \| F11 antibody \| FA11_HUMAN antibody \| FXI antibody \| MGC141891 antibody \| Plasma thromboplastin antecedent antibody \| Platelet coagulation factor XI antibody \| PTA antibody \| Co
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
生化机理	Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
宿主种属	人(Human)
特异性	F11
种属反应性	人(Human)
偶联	Unconjugated
作用类型	抑制剂
作用机制	整合素 αIIbβ3 抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	lambda
SDS-PAGE	27.4 kDa (Light Chain) & 50.4 kDa (Heavy Chain), under reducing conditions; 197.4kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	长期储存-80℃（24个月）；收货后建议分装，避免反复冻融。
CAS编号和信息	2098724-83-3
分子类型	抗体

关联靶点（人）

F11 Tchem 凝血因子 XI(Coagulation factor XI) (0 活性数据)

点击查看靶蛋白信息： F11

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

ITGA2B Tclin 整合素α-IIb(Integrin alpha-IIb) (0 活性数据)

点击查看靶蛋白信息： ITGA2B

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

ITGB3 Tclin 整合素β-3(Integrin beta-3) (0 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

ITGA2B Tclin Integrin alpha-IIb (36 活性数据)

点击查看靶蛋白信息： ITGA2B

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

F11 Tchem Coagulation factor XI (1733 活性数据)

点击查看靶蛋白信息： F11

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Integrin alpha-V/beta-3 (2708 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Integrin alpha-IIb/beta-3 (3481 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Fibronectin receptor (Integrin alpha-5/beta-1 and alpha-V/beta-3) (39 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Integrin alpha-V/beta-3 and alpha-IIb/beta 3 (49 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Integrin alpha-2/beta-3 (21 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ITGB3 Tclin Integrin alpha-3/beta-3 (47 活性数据)

点击查看靶蛋白信息： ITGB3

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

SEC: Abelacimab (anti-Factor XI) (Ab175444)

Abelacimab (anti-Factor XI) (Ab175444) - SEC
The purity of Abelacimab (anti-Factor XI) (Ab175444) is more than 95% verified by HPLC.

ELISA: Abelacimab (anti-Factor XI) (Ab175444)

Abelacimab (anti-Factor XI) (Ab175444) - ELISA
Immobilized Human F11-his at 2.0 μg/mL can bind Abelacimab (anti-Factor XI) (Ab175444) with the EC₅₀ of 31.79 ng/mL.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到8个结果

批号(Lot Number)	证书类型	货号
ZJ25F0723625	分析证书	Ab175444
ZJ25F0723626	分析证书	Ab175444
ZJ25F0723627	分析证书	Ab175444
ZJ25F0319650	分析证书	Ab175444
ZJ24F0607383	分析证书	Ab175444
ZJ24F0202895	分析证书	Ab175444
ZJ24F0202894	分析证书	Ab175444
ZJ24F0202893	分析证书	Ab175444

可替换产品

引用文献

1. Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M et al.. (2022) Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.. J Thromb Haemost, 20 (2): (307-315). [PMID:34714969]
2. Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, McCormack P, Yu J, Huang X, Chiu YH et al.. (2019) MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.. Blood, 133 (13): (1507-1516). [PMID:30692123]
3. Weitz JI, Chan NC. (2019) MAA868 locks factor XIa in a zymogen-like state.. Blood, 133 (13): (1393-1394). [PMID:30923107]
4. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H. (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.. J Med Chem, 52 (18): (5732-47). [PMID:19715320]
5. Di Scipio RG, Kurachi K, Davie EW. (1978) Activation of human factor IX (Christmas factor).. J Clin Invest, 61 (6): (1528-38). [PMID:659613]
6. Schaefer M, Buchmueller A, Dittmer F, Straßburger J, Wilmen A. (2019) Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.. J Mol Biol, 431 (24): (4817-4833). [PMID:31655039]
7. Lin J, Deng H, Jin L, Pandey P, Quinn J, Cantin S, Rynkiewicz MJ, Gorga JC, Bibbins F, Celatka CA, Nagafuji P, Bannister TD, Meyers HV, Babine RE, Hayward NJ, Weaver D, Benjamin H, Stassen F, Abdel-Meguid SS, Strickler JE.. (2006) Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.. J Med Chem, 49 (26): (7781-7791). [PMID:17181160] [10.1021/jm060978s]
8. Sidhu PS, Mosier PD, Zhou Q, Desai UR.. (2013) On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans.. Bioorg Med Chem Lett, 23 (1): (355-359). [PMID:23164711] [10.1016/j.bmcl.2012.10.079]
9. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR.. (2013) Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.. J Med Chem, 56 (3): (867-878). [PMID:23316863] [10.1021/jm301338q]
10. Karuturi R, Al-Horani RA, Mehta SC, Gailani D, Desai UR.. (2013) Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.. J Med Chem, 56 (6): (2415-2428). [PMID:23451707] [10.1021/jm301757v]
11. Wang TC, Qiao JX, Clark CG, Jua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Everlof G, Schumacher WA, Wong PC, Seiffert DA, Stewart AB, Bostwick JS, Crain EJ, Watson CA, Rehfuss R, Wexler RR, Lam PY.. (2013) Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.. Bioorg Med Chem Lett, 23 (11): (3239-3243). [PMID:23602442] [10.1016/j.bmcl.2013.03.125]
12. Abdel-Magid AF.. (2014) Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.. ACS Med Chem Lett, 5 (4): (286-287). [PMID:24900827] [10.1021/ml500084u]
13. Argade MD, Mehta AY, Sarkar A, Desai UR.. (2014) Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.. J Med Chem, 57 (8): (3559-3569). [PMID:24666186] [10.1021/jm5002698]
14. Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.. (2016) Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.. J Med Chem, 59 (15): (7125-7137). [PMID:27455395] [10.1021/acs.jmedchem.6b00469]
15. Middendorp SJ, Wilbs J, Quarroz C, Calzavarini S, Angelillo-Scherrer A, Heinis C.. (2017) Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity.. J Med Chem, 60 (3): (1151-1158). [PMID:28045547] [10.1021/acs.jmedchem.6b01548]
16. Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC, Bachovchin DA, Cook GM, Apte M, Huang M, Ranson M, Kelso MJ.. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.. J Med Chem, 61 (18): (8299-8320). [PMID:30130401] [10.1021/acs.jmedchem.8b00838]
17. Fischer PM.. (2018) Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.. J Med Chem, 61 (9): (3799-3822). [PMID:29072911] [10.1021/acs.jmedchem.7b00772]
18. Morla S, Sankaranarayanan NV, Afosah DK, Kumar M, Kummarapurugu AB, Voynow JA, Desai UR.. (2019) On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.. J Med Chem, 62 (11): (5501-5511). [PMID:31074986] [10.1021/acs.jmedchem.9b00379]
19. Chen P, Zhang D, Li M, Wu Q, Lam YPY, Guo Y, Chen C, Bai N, Malhotra S, Li W, O'Connor PB, Fu H.. (2019) Discovery of novel, potent, isosteviol-based antithrombotic agents.. Eur J Med Chem, 183 (111722-111722). [PMID:31563807] [10.1016/j.ejmech.2019.111722]
20. Wang D, Yang Y, Jiang L, Wang Y, Li J, Andreasen PA, Chen Z, Huang M, Xu P.. (2019) Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.. J Med Chem, 62 (4): (2172-2183). [PMID:30707839] [10.1021/acs.jmedchem.8b01908]
21. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N. (2020) Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.. J Med Chem, 63 (17): (9856-9875). [PMID:32856916] [10.1021/acs.jmedchem.0c01020]
22. Meijers, J C JC, Davie, E W EW and Chung, D W DW.. (1992) Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency.. Blood, (15): [PMID:1547342]
23. McMullen, B A BA, Fujikawa, K K and Davie, E W EW.. (1991) Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains.. Biochemistry, (26): [PMID:1998667]
24. Asakai, R R, Chung, D W DW, Ratnoff, O D OD and Davie, E W EW.. (1989) Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2813350]
25. Asakai, R R, Davie, E W EW and Chung, D W DW.. (1987) Organization of the gene for human factor XI.. Biochemistry, (17): [PMID:2827746]
26. Meijers, J C JC and 5 more authors.. (1988) Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.. Biochemistry, (14): [PMID:2844223]
27. Imanaka, Y Y and 5 more authors.. (1995) Identification of two novel mutations in non-Jewish factor XI deficiency.. British journal of haematology, [PMID:7669672]
28. Pugh, R E RE, McVey, J H JH, Tuddenham, E G EG and Hancock, J F JF.. (1995) Six point mutations that cause factor XI deficiency.. Blood, (15): [PMID:7888672]
29. Wistinghausen, B B and 5 more authors.. (1997) Severe factor XI deficiency in an Arab family associated with a novel mutation in exon 11.. British journal of haematology, [PMID:9401068]
30. Hsu, T C TC, Shore, S K SK, Seshsmma, T T, Bagasra, O O and Walsh, P N PN.. (1998) Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene.. The Journal of biological chemistry, (29): [PMID:9593722]
31. Martincic, D D and 5 more authors.. (1998) Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting.. Blood, (1): [PMID:9787168]
32. Alhaq, A A and 8 more authors.. (1999) Identification of a novel mutation in a non-Jewish factor XI deficient kindred.. British journal of haematology, [PMID:10027710]
33. Mitchell, M M and 7 more authors.. (1999) Heterozygous factor XI deficiency associated with three novel mutations.. British journal of haematology, [PMID:10606881]
34. Badellino, K O KO and Walsh, P N PN.. (2001) Localization of a heparin binding site in the catalytic domain of factor XIa.. Biochemistry, (26): [PMID:11412111]
35. Zivelin, Ariella A and 6 more authors.. (2002) Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene.. Blood, (1): [PMID:11895778]
36. Kravtsov, Dmitri V DV and 7 more authors.. (2004) Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain.. Blood, (1): [PMID:15026311]
37. Cicardi, Marco M, Zingale, Lorenza L, Zanichelli, Andrea A, Pappalardo, Emanuela E and Cicardi, Benedetta B.. (2005) C1 inhibitor: molecular and clinical aspects.. Springer seminars in immunopathology, [PMID:16267649]
38. Liu, Tao T and 6 more authors.. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952]
39. Quélin, Florence F and 10 more authors.. (2006) Identification of five novel mutations in the factor XI gene (F11) of patients with factor XI deficiency.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, [PMID:16607084]
40. Fard-Esfahani, P P and 6 more authors.. (2008) Seven novel point mutations in the F11 gene in Iranian FXI-deficient patients.. Haemophilia : the official journal of the World Federation of Hemophilia, [PMID:18005151]
41. Dai, L L, Rangarajan, S S and Mitchell, M M.. (2011) Three dominant-negative mutations in factor XI-deficient patients.. Haemophilia : the official journal of the World Federation of Hemophilia, [PMID:21457405]
42. Kim, J J and 9 more authors.. (2012) Population-specific spectrum of the F11 mutations in Koreans: evidence for a founder effect.. Clinical genetics, [PMID:21668437]
43. Girolami, Antonio A and 6 more authors.. (2012) A cluster of factor XI-deficient patients due to a new mutation (Ile 436 Lys) in northeastern Italy.. European journal of haematology, [PMID:21999818]
44. Lee, Jong Ho JH, Cho, Hee Soon HS, Hyun, Myung Soo MS, Kim, Hwa-Young HY and Kim, Hee-Jin HJ.. (2011) A novel missense mutation Asp506Gly in Exon 13 of the F11 gene in an asymptomatic Korean woman with mild factor XI deficiency.. The Korean journal of laboratory medicine, [PMID:22016685]
45. Guéguen, Paul P and 6 more authors.. (2012) Revisiting the molecular epidemiology of factor XI deficiency: nine new mutations and an original large 4qTer deletion in western Brittany (France).. Thrombosis and haemostasis, [PMID:22159456]
46. Tirefort, Yordanka Y, Uhr, Mario R MR, Neerman-Arbez, Marguerite M and de Moerloose, Philippe P.. (2012) Identification of a novel F11 missense mutation (Ile463Ser) in a family with congenital factor XI deficiency.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, [PMID:22322133]
47. Faid, Valegh V, Denguir, Nouha N, Chapuis, Violaine V, Bihoreau, Nicolas N and Chevreux, Guillaume G.. (2014) Site-specific N-glycosylation analysis of human factor XI: Identification of a noncanonical NXC glycosite.. Proteomics, [PMID:25092234]
48. Keskin, Ebru Ylmaz EY and 7 more authors.. (2015) Molecular basis and bleeding manifestations of factor XI deficiency in 11 Turkish families.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, [PMID:25158988]
49. Fujikawa, K K, Chung, D W DW, Hendrickson, L E LE and Davie, E W EW.. (1986) Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein.. Biochemistry, (6): [PMID:3636155]
50. Cargill, M M and 17 more authors.. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes.. Nature genetics, [PMID:10391209]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Abelacimab (anti-Factor XI), 整合素 αIIbβ3 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器